CELC.US Celcuity LLC

Healthcare Biotechnology USA Stocks
64.37 USD
Close of Nov 14, 2026
53.54 151.02
Market cap
USD 3.15B
P/E
-
P/B
78.90x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CELC.US undervalued?

Graham number

The Graham number of Celcuity LLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Celcuity LLC fundamental analysis

No fundamental analysis for Celcuity LLC yet.

Celcuity LLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Celcuity LLC

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth …

Full company profile